natgillin/translations-raw huggingface dataset:
A method according to claim 27, wherein after the incubation step at least a portion of the hatching medium, which contains free swimming live food organisms and unhatched cysts, is removed from the hatching container and is guided along at least one magnet so that unhatched cysts stick to said magnet while the free swimming live food organisms pass said magnet. 
Uporaba prema bilo kojem od zahtjeva 10 do 12, naznačena time što se nakon koraka inkubacije barem dio medija za leženje, koji sadrži žive organizme koji slobodno plivaju i služe kao hrana te neizlegmute ciste, uklanja iz spremnika za leženje i provodi duž barem jednog magneta tako da neizlegnute ciste ostanu pričvršćene za taj magnet dok živi organizmi koji slobodno plivaju i služe kao hrana prolaze duž magneta, t>&
In a further embodiment of the methods disclosed, the patient-reported total injection pain rating experienced five minutes following subcutaneous injection is reduced by about 31%. In another embodiment of the methods disclosed, the pain is the immediate pain presence following the subcutaneous injection. 
Jedinična doza prema patentnom zahtjevu 10, naznačena time, da ocjena ukupne boli od injekcije, pretrpljene pet minuta nakon supkutane injekcije, o čemu se izjašnjava pacijent, jest smanjena za oko 31%.
purifying memory B cells which do not express IgM from the sample in which the antibody which binds to said specimen but not to tissue ithout said pathological structures is present; 
(b) utvrđivanje prisutnosti protutijela u uzorku koja se vežu na navedeni uzorak, ali ne na odgovarajuće tkivo zdravih osoba bez takvih patoloških struktura;
A header 90 could include a receiver 30 for one or more bottles 20. In Figures 6A-C, two APPLI-PRO™ bottles 20A and B can be screwed into operative position to receivers 30A and B respectively. This provides easy access for the operator to connect or remove either bottle 20A or B to device 10. 
Glavni nosač 90 može obuhvaćati nosač 30 za jednu ili više boca 20, Prema slikama 6A-C, dve APPLIPROTM boce 20A 1 20B mogu se uvrnuti u radni položaj na nosačima 30A 1 30B. To osigurava lagani pristup operateru da priključi ili da ukloni jednu od boca 20A ili 20B u, ili iz uređaja 10.
In a further embodiment the invention also relates to use of a compound of the invention as the free base or a salt thereof for the preparation of a pharmaceutical composition for the treatment of depression. 
U jednom daljnjem obliku izum se također odnosi na korištenje spoja izuma kao slobodne baze ili njezine soli za pripravak farmaceutskog sastava kod liječenja depresije.
(b) heating the mixture to obtain a substantially homogenous solution, 
(b) = zagrijavanje smjese radi dobivanja u biti homogene otopine,
Fan unit according to claim 7, wherein the outlet orifices are disposed in the front wall and respectively extend in an outwardly inclined arrangement in their flow direction towards the side facing away from the nozzle head axis. 
Ventilatorska jedinica (1) prema zahtjevu 13 ili 14, naznačena time da su izlazni otvori (33) raspoređeni na prednjoj stjenci (34) na način da su zasebno usmjereni u smjeru njihovog protoka prema dijelu udaljenom od osi glave mlaznice (32) i bivaju nagnuti prema van.
Particularly suitable compositions for oral administration are unit dosage forms such as tablets and capsules. 
Pripravci osobito pogodni za oralnu primjenu su oblici jedinica doziranja poput tableta i kapsula.
or an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. 
Spoj sukladno zahtjevu 1, naznačen time, da je spoj N-oksid te vrste, farmaceutski prihvatljiva sol te vrste ili solvat te vrste.
comprising STEP A: dissolving a compound of formula (I-S) in an organic solvent; 
KORAK A: otapanje spoja formule (I-S) u organskom otapalu, pri čemu je organsko otapalo izopropil acetat;
the engage members of each carrier are positioned relative to each other such that said engage members form a triangle. 
- zahvatni članovi svakog nosača su međusobno postavljeni tako da rečeni zahvatni članovi čine trokut (35).
To this solution was added diethyl oxalate (20 mL) and the mixture was heated to reflux with removal of ethanol by Dean-Stark trap. 
U tu se otopinu doda dietil oksalat (20 mL) i smjesa se zagrijava uz povrat uz uklanjanje etanola uz Dean-Starkovu posudu.
The process according to claim wherein, in step f), the flame retardant agent and synergist are blended, in a separate extruder, with the vinyl aromatic polymer before being introduced in the main polymer melt stream, comprising the comminuted needle petroleum coke particles and the foam cell regulator. 
Postupak prema zahtjevu 8 naznačeno time da, u koraku f., agent za usporavanje gorenja i sinergist su umješani, u zasebnoj preši, sa vinil aromatskim polimerom prije negoli su uvedeni u tok rastapanja glavnog polimera, koji sadrži usitnjene čestice igličastog koksa 1 FOAM CELL REGULATOR
The suspension system according to claim 1, wherein the floating support securing elements, in particular floating support securing elements designed as framework elements of a frame structure, do not intersect the longitudinal axis of the inner container. 
Spremnički sklop (20, 21, 21′, 22, 22′, 23, 24, 25, 26, 27) u skladu s patentnim zahtjevom 11, naznačen time što slobodni nosivi osiguravajući elementi (11), osobito slobodni nosivi osiguravajući elementi dizajnirani kao rešetkasti elementi okvirne konstrukcije, ne presijecaju uzdužnu os (L2) unutarnjeg spremnika (2).
The solution was filtered through a 0.45 µm PVDF filter. 
Otopina je filtrirana kroz 0.45 um PVDF filter.
casting the aluminum alloy of claim 1 to form an ingot or a slab; 
lijevanju aluminijske legure u skladu s patentnim zahtjevom 1 kako bi se dobilo ingot ili bramu;
According to an aspect of the present invention it is provided, that the inner bonding layer is free of thermochromic colouring agents. 
Alat za brušenje (1) sukladno jednom od prethodnih zahtjeva, naznačen time što je unutarnji sloj za povezivanje (10) bez termokromatskih agensa za bojanje.
The isolated protein of claim 1, which binds to human Her2 with a binding affinity of Kd<10−8 M. 
(1) afinitet vezanja za cilj od Kd<10-8 M ili IC50<10-8 M, i
In still another embodiment, the invention provides soft chewable compositions comprising abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, milbemycin A3, milbemycin A4, milbemycin oxime, moxidectin or nemadectin, or a combination thereof. 
Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 26, naznačen time, da makrociklički lakton je eprinomektin, ivermektin, selamektin, abamektin, dimadektin, doramektin, emamektin, latidektin, lepimektin, milbemektin, milbemicin D, milbemicin A3, milbemicin Ay, milbemicin oksim, moksidektin ili nemadektin, ili njihova kombinacija.
The anti-VEGF antagonist antibody and/or anti-alpha5beta1 antagonist antibody for use according to claim 10, wherein the cytotoxic agent is a radioactive isotope, chemotherapeutic agent or a toxin. 
Protutijelo antagonista anti-VEGF i/ili protutijelo antagonista anti-alfa5betal, za uporabu prema zahtjevu 10, naznačen/i time, da citotoksično sredstvo je radioaktivni izotop, kemoterapeutsko sredstvo ili toksin.
Method according to claim 1 or 2, wherein water and/or the inorganic oxoacid compound and/or its salt is removed from the reaction mixture. 
Postupak prema zahtjevu 1 ili 2, pri čemu se voda i/ili neorganski oksokiselinski spoj ifili njegova sol odstranjuju iz reakcijske smjese.
Method for the production of a form of administration of a medicament 
POSTUPAK ZA PROIZVODNJU OBLIKA ZA DAVANJE LIJEKA
The method of claim 1 wherein the R,R-glycopyrrolate and formoterol are presented in fixed or free combination for simultaneous, sequential or separate administration, optionally together with a suitable excipient, adjunct or additive in a pharmaceutical form suitable for inhalative application. 
Postupak prema patentnom zahtjevu 8, naznačen time, da su djelatne tvari raspoložive u fiksnoj kombinaciji, po potrebi zajedno s uobičajenim nosiocima, pomoćnim tvarima i dodacima, u farmaceutskom obliku prikladnom za inhalacijsku primjenu.
The thieno[3,2-d]pyrimidine derivative or its pharmaceutically acceptable salt of embodiment 1, which is selected from the group consisting of: 
5. = Derivat tieno[3,2-d]pirimidina, koji je izabran iz skupine koja se sastoji od:
A compound according to claim 13, wherein the reverse transcriptase of the multiresistant HIV bears at least one mutation that allows an obligate chain terminating nucleoside- or nucleotide phosphate to be excised from the nascent DNA strand by ATP- or pyrophosphate-mediated excision. 
Spoj prema zahtjevu 13, gdje reverzna transkriptaza multirezistentnog HIV-a nosi barem jednu mutaciju koja omogućuje da obvezni krajevi lanca nukleozid- ili nukleolid- fosfati budu izrezani iz nasceninog (rastućeg) DNA lanca pomoću ATP- ili pirofosfat- posredovanog izrezivanja.
The process according to claim 7 wherein the virus is an orthomyxovirus, a recombinant orthomyxovirus or a reassorted orthomyxovirus selected among human influenza virus, avian influenza virus, swine influenza virus, equine influenza virus, feline influenza virus. 
ortomiksovirus, rekombinantni ortomiksovirus ili reasortirani orthomiksovirus izabran između virusa ljudske gripe, virusa ptičje gripe, virusa svinjske gripe, virusa konjske gripe, virusa mačje gripe;
These salts may be prepared from compounds of formula (I) by known salt-forming procedures. 
Te se soli mogu dobiti iz spojeva formule (1) postupcima koji su dobro poznati za tvorbu soli.
transfection of the cells is carried out with a mixture of PEI and the required plasmid(s); 
- < transficiranje stanica se provodi smjesom PEI s jednim ili više potrebnih plazmida;
Alternatively the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use. 
Alternativno aktivni sastojak može biti u obliku praha za pripravu s pogodnim vehikulumom, primjerice sterilnom, apirogenom vodom, prije upotrebe.
The topical veterinary composition of clause 4, wherein the diester of a dicarboxylic acid is a diester of a C6-C16 dicarboxylic acid. 
Topikalni veterinarski pripravak prema zahtjevu 1, naznačen time, da nosač obuhvaća C;-Cy-dialkilester od dikarboksilne kiseline.
Further concentration gave regioisomers of I-benryl-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid amide and 2-benzyl-1,4,5,6-tetrahydro-cyclopentapyrazole-3-carboxylic acid amide (65.3 g, 270 mmol, 98% yield) as a 20: 1 mixture and was used without separation). 
Daljnje koncentriranje daje regioizomere amida 1-benzil-1,4,5,6-tetrahidrociklopentapirazol-3-karboksilne kiseline i amida 2-benzil-1,4,5,6-tetrahidro-ciklopentapirazol-3-karboksilne kiseline (65.3 g, 270 mmol, 98% prinosa) kao 20:1 smjesu i koristi se bez odijeljivanja.
A solution of 4-(bromomethyl)biphenyl, 1,12 g (4.53 mmol), in 5 mL tetrahydrofuran (THF) was added and the solution stirred under argon bubbling for 8 hours at room temperature. The THF was removed by rotary evaporation under vacuum and the residue diluted with water and washed with diethyl ether. 
Dodana je otopina 4-(bromometil)bifenila, 1.12 g (4.53 mmol), u 5 ml tetrahidrofurana (THF) i otopina je miješana pod argonom 8 sati kod sobne temperature.THY je uklonjen rotacionim uparivanjem pod vakuumom a ostatak je razrijeđen vodom 1 ispran dietil eterom.
The topical veterinary composition of claim 14, wherein the insect growth regulator is (S)-methoprene, pyriproxyfen, hydroprene, cyromazine, fluazuron, lufenuron, or novaluron. 
Topikalni veterinarski pripravak prema zahtjevu 10, naznačen time, da je regulator rasta kukaca (S)-metopren, piriproksifen, hidropren, ciromazin, fluazuron, lufenuron ili novaluron.
A pharmaceutical composition comprising a compound of claim 1, or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier, diluent or excipient. 
Farmaceutski pripravak, naznačen time, da sadrži spoj iz bilo kojeg od patentnih zahtjeva 1-22 ili stereoizomer, farmaceutski prihvatljivu sol i farmaceutski prihvatljiv nosač, razrjeđivač ili ekscipijens.
A pharmaceutical aerosol solution composition according to any one of the previous paragraphs wherein the stabilising amount of a mineral acid is an amount of acid equivalent to 1M hydrochloric acid in the range from 0.15 to 0.28 mcg/mcl. 
Farmaceutski pripravak aerosolne otopine prema patentnom zahtjevu 1 ili 2 u kojem stabilizirajuća količina mineralne kiseline jest količina kiseline ekvivalentna IM klorovodične kiseline u rasponu od 0,15 do 0,28 ug/ul.
In a preferred embodiment, before, during, or after step c), but before step d), at least one earth alkali oxide and/or hydroxide, preferably lime and/or burnt dolomite is added to the aqueous suspension of step b), wherein lime in the context of the present invention comprises calcium oxide and calcium hydroxide. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da prije, tijekom ili nakon koraka c), ali prije koraka d), se u vodenu suspenziju iz koraka b) dodaje barem jedan oksid i/ili hidroksid zemnoalkala, poželjno vapnenac i/ili spaljeni dolomit.
reacting the compound of Formula LXXIII with a compound of Formula LXXIV 
Formula LXXIY čime se dobiva spoj Formule LXXV; i
said longitudinal profile groove (122) having, at a lower part thereof, an undercut portion (129) adjacent to and inside a ridge portion (128) of the key blade, the outside of said ridge portion forming a part of said side surface (123) of the key blade, 
navedeni uzdužni profil utora (122) ima podrezani dio (129) koji je pored i unutar dijela grebena (125) oštrice ključa, a vanjska strana navedenog dijela grebena tvori dio navedene bočne površine (123) oštrice ključa, naznačen time da -
is a charge neutral masking agent comprising a galactose or galactose derivative having affinity for the asialoglycoprotein receptor, 
tvorbu prvog maskirajućeg sredstva koje sadrži disupstituirani maleatni anhidrid neutralnog naboja koji sadrži derivat galaktoze;
associating each of the extracted first-type syntax elements with a respective associated position within the transform coefficient block in a scan order, the scan order being related to positions of significant transform coefficients indicated by previous first-type syntax elements. 
Postupak za kodiranje signifikacijske mape u protok podataka, koja prikazuje pozicije signifikantnih koeficijenata transformacije unutar bloka koeficijenata transformacije, naznačen time, da taj postupak obuhvaća sljedeće:
said drive devices (2) include a rotary support (3) to be rotated to control the movement of said first engagement means (8) from the engagement position to the disengagement position and vice versa; 
- < pogonska sredstva (2) obuhvaćaju okretnu potporu (3) koja se rotira radi kontrole kretanja prvih sredstava za zahvaćanje (8) iz zahvaćenog u odvojeni položaj i obrnuto;
A cell culture device, wherein said culture device contains a volume of at least 5 L of a serum-free culture medium comprising mammalian cells, such as HEK 293T cells, transfected with at least one plasmid adapted for the production of a lentiviral vector, said cells growing in suspension in said culture device. 
Naprava za uzgoj stanica, naznačena time što navedena naprava za uzgoj sadrži volumen od najmanje 50 1 uzgojnog medija koji ne sadrži serum, koji sadrži stanice HEK 293€T, transficirane najmanje jednim plazmidom prilagođenim za proizvodnju lentivirusnog vektora, gdje navedene stanice rastu u suspenziji u navedenoj napravi za uzgoj.
wherein is selected from the group consisting of —OH, ORa, and NRbRc; 
R! je odabran iz skupine koju čine -OH, OR*, i NR*R";
The method as claimed in claim 5, wherein said aqueous alcohol is selected from the group consisting of ethanol, methanol, n-propanol, 2-propanol, glycerol, PEG, PPG, ethylene glycol and propylene glycol. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što navedeni vodeni alkohol se bira iz skupine koju čine etanol, metanol, n-propanol, 2-propanol, glicerol, PEG, PPG, etilen-glikol i propilen-glikol.
A process for making a container according to any of claims 1 to 6, wherein the process comprises: providing a container comprising a base and a continuous side wall upstanding from the base with a peripheral flange formed along the upper, in use, edge of the continuous side wall, thereby forming a tray, wherein said base and side wall consist essentially of polyethylene terephthalate (PET), and at least one denesting recess located in a denesting area, wherein the denesting area is relieved relative to the upper surface of the flange and extends partially or completely along the inner periphery of the flange, and 
Postupak izrade posuda prema bilo kojem od patentnih zahtjeva 1 do 9, pri čemu postupak sadrži: a) = pružanje posude koja sadrži osnovu i kontinuirani bočni zid koji se proteže čvrsto okomito na osnovu sa obodom formiranim duž gornjeg, pri upotrebi, ivice kontinuiranog bočnog zida, pri čemu se osnova i kontinuirani bočni zid u osnovi sastoje od polietilen tereftalata (PET); i b) nanošenje sloja ljepila na gornju, pri upotrebi, površinu oboda kako bi se stvorila pričvršćenzatvorena posuda i sloj ljepila se ne širi na vertikalne, pri upotrebi, površine kontinuiranog bočnog zida i ne Å iri se na osnovu
metformin for use in a method of preventing or treating diabetes mellitus, diseases associated with diabetes mellitus, or complications of diabetes mellitus, wherein (A) and (B) are administered to a patient in need either simultaneously or separately. 
metformina naznačena time da je za uporabu u postupku prevencije ili liječenja dijabetes melitusa, bolesti povezanih sa dijabetes melitusom, ili komplikacijama dijabetes melitusa, pri čemu se (A) i (B) daju pacijentu kojemu je to potrebno bilo istovremeno ili odvojeno.
An isolated nucleic acid encoding the antibody or an antigen-binding fragment thereof according to any one of claims 1 to 8. 
Izolirana nukleinska kiselina, naznačena time što kodira protutijelo protiv čimbenika D, ili njegov fragment koji se veže na čimbenik D, u skladu s bilo kojim od patentnih zahtjeva 1 do 11.
is SR or -COR, wherein R is linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 - 10 carbon atoms, or simple or substituted aryl or heterocyclic aromatic or heterocycloalkyl radical. 
je SR ili -COR, pri čemu je R linearni alkil ili alkenil s 1 do 10 atoma ugljika, razgranati ili ciklički alkil ili alkenil s 3 do 10 atoma ugljika, ili jednostavni ili supstituirani aril ili heterociklički aromatski ili heterocikloalkilni radikal.
U2N and the time angle is a < 15°, and at the same time, the separating switch (2.1) is on and the voltage in the MV supply Line (2.11) of the capacitive voltage divider (2.5) of the MV switchgear (2) is also present. 
U2N i vremenski kut je a <15°, a istovremeno, prekidač odvajanja (2.1) je u položaju uključeno, a prisutan je i napon u SN napajanju (2.11) kapacitivnog djelitelja napona (2.5) na SN razvodnom uređaju (2).
The compound for use according to claim 4, wherein the agent is for treating scleroderma. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što je sredstvo za liječenje skleroderme.
The kit of any one of claims 6 to 10 for use in treatment of a neurological disorder selected from: restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, or Parkinson's like syndrome, by continuously administering the first composition in conjunction with the second composition. 
Komplet iz bilo kojeg od patentnih zahtjeva 6 do 10, naznačen time, da je namijenjen upoirebi u liječenju neurološkog poremećaja odabranog od: sindroma nemirmih nogu, Parkinsonove bolesti, sekundarnog parkinsonizma, Huntingtonove bolesti ili sindroma sličnog Parkinsonovoj bolesti, kontinuiranim davanjem prvog pripravka zajedno s drugim pripravkom.
Furthermore with reference to figure 3, it can be observed from a microcrystalline analysis of the structure of a steel strip according to the invention that more than 80% of the grains, detected on average at various positions on the strip and statistically for a number of strips, has lower dimensions than those corresponding to grade 10 of the ASTM E112 standard, and consequently a better fineness than that grade. 
Pored toga, u svezi sa slikom 3, može se vidjeti iz mikrokristalne analize strukture čelične trake prema izumu da više od 80% zrna, detektiranih u prosjeku na različitim položajima na traci i statistički za određen broj traka, ima manje dimenzije od onih koji odgovaraju stupnju 10 - ASTM E112 standarda, i posljedično bolju finoću od tog stupnja,
an electrical circuit electrically connecting said motor to a mains; 
strujni krug koji spaja navedeni elektromotor s glavnim vodom;
An anticancer agent comprising the CAR-expressing T cell according to claim 8 and a pharmaceutically acceptable additive. 
Sredstvo protiv raka koje sadrži T stanicu u skladu s patentnim zahtjevom 9 i farmaceutski prihvatljiv aditiv.
A host cell as defined in any one of claims 1 to 2, wherein the first vector comprises a nucleic acid molecule of SEQ ID NO: 63. 
Molekula nukleinske kiseline u skladu s patentnim zahtjevom 3, naznačena time što sadrži SEQ ID NO:61 i SEQ ID NO:63.
The process of claim 8 wherein the further antigens comprise one or more S.pneumoniae proteins selected from the group consisting of the Poly Histidine Triad family (PhtX), Choline Binding Protein family (CbpX), CbpX truncates, LytX family, LytX truncates, CbpX truncate-LytX truncate chimeric proteins (or fusions), pneumolysin (Ply), PspA, PsaA, Sp128, Sp101, Sp130, Sp125 and Sp133. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što dodatni antigeni uključuju jedan ili više proteina iz bakterije S. pneumoniae, koji se biraju iz skupine koju čine obitelj polihistidinske trijade (PhtX), obitelj kolinski vežućeg proteina (CbpX), skraćeni CbpX, obitelj LytX, skraćeni LytX, kimerini proteini (ili fuzije) skraćeni CbpX-skraćeni LytX, pneumolizin (Ply), PspA, PsaA, Sp128, Sp101, Sp130, Sp125 i Sp133.
Floating structure according to claim 10, characterised in that the floating structure is a ship (1) for laying cables on or in the bed of a body of water. 
Plutajuća struktura sukladno zahtjevu 10, naznačena time što je plutajuća struktura brod (1) za polaganje kablova na ili u ležaj u vodi.
heavy and light chains encoded by nucleotide sequences comprising sequences which are at least 90%, 95%, 98% or 99% identical to sequences of SEQ ID NO:11, and SEQ ID NO:47, 59, 61, or 63, respectively. 
teške i lake lance koje kodiraju nukleotidni sljedovi koji sadrže sljedove koji su najmanje 90%, 95%, 98% ili 99% istovjetni sljedovima sa SEQ ID NO:11 odnosno SEQ ID NO:47, 59, 61 ili 63.
adjusting the pH of the mixture in the API-vessel of step k to below 2 by using an acid, selected from a group comprising acids such as HCl, H2So4, HN03, Lactic acid and the like, either singly or any combination thereof, preferably Nitric acid in an amount between 0.005% (w/w) to 0.5% (w/w), preferably 0.3% (w/w), more preferably 0.25% (w/w), 
HR P20130515 T1 podešavanje pH smjese u API-posudi iz stupnja k na ispod 2 korištenjem kiseline, odabrane iz skupine koja sadrži kiseline. kao što su na primjer HC1, H2SO4, HNO;, mliječna kiselina 1 slične, ili pojedinačno ili bilo koju njihovu kombinaciju, prvenstveno dušične kiseline u količini između 0,005% (tež.) do 0,5% (tež.), prvenstveno 0,3% (tež.), pogodnije 0,25% (tež.),
Preferred are 30 to 85% by weight of latently hydraulic and/or pozzolanic material and 15 to 70% by weight of ternesite, more preferably 40 to 80% by weight of latently hydraulic material and 20 to 60% by weight of ternesite, wherein the values are relative to the total quantity of binder, and the portions in combination with those of the remaining binder components add up to 100%. 
- CM od 5 do 80% težine, poželjno 20 do 60% težine i najbolje od 30 do 50% težine, pri čemu su vrijednosti relativne u odnosu na ukupnu količinu vezivnog sredstva, zajednički iznose do 100% zajedno s preostalim komponentama vezivnog sredstva (o; B) C2S